急性脑梗死应用依达拉奉治疗的用药效果初步评价  

Preliminary Evaluation of the Effect of Drug Use on Acute Cerebral Infarction Treated by Edaravone

作　　者：杨训永[1] 

机构地区：[1]成都市第三人民医院,四川成都610031

出　　处：《中国医药指南》2016年第24期20-21,共2页Guide of China Medicine

摘　　要：目的评价急性脑梗死应用依达拉奉治疗的临床效果。方法本次研究患者为我院2014年9月至2015年9月期间收治的急性脑梗死患者180例,随机将患者分为对照组和观察组每组患者90例,两组患者在性别、平均年龄、平均发病时间等基本资料上无统计学差异(P>0.05)可进行组间比较。两组患者均接受脑梗死常规治疗,给予患者银杏叶提取物注射液,同时口服阿司匹林,根据患者病情给予抗高血压、调脂、控制血糖等规范化治疗。观察组患者使用依达拉奉注射液;对照组患者使用安慰剂注射液,安慰剂中不含有依达拉奉,且符合安慰剂的制备要求,外观和形态与依达拉奉相同。观察两组患者治疗前和治疗后7、14、21 d的NIHSS评分(神经功能缺损评分)和Barthel指数(BI)评分(ADL日常生活能力评分),根据神经功能缺损评分和日常生活能力评分的变化情况进行疗效评价。结果两组患者经过治疗后,第7天的NIHSS评分和BI评分改变均优于治疗前的NIHSS评分和BI评分,观察组和对照组患者在治疗后第7天的NIHSS评分和BI评分无统计学差异(P>0.05);在治疗后第14天、第21天观察组的NIHSS评分和BI评分改变均明显优于对照组患者,两组NIHSS评分和BI评分差异具有统计学意义(P<0.05),观察组患者的神经功能缺损改善情况明显高于对照组患者,且P<0.05具有统计学差异,在治疗中两组治疗中出现不良反应的患者均未得到特殊治疗自行好转,两组患者不良反应率无统计学差异。结论依达拉奉静脉注射可有效改善急性脑梗死患者的神经功能缺失和日常生活能力,也可改善脑梗死患者的远期生活能力,无明显不良反应,值得在临床上广泛应用。Objective Adrmentioned application evaluation of acute cerebral infarction and the clinical effect of treatment. Methods The study in the patients of our hospital between September 2014 and September 2015 admitted during the period of 180 patients with acute cerebral infarction were randomly divided the patients into control group and observation group of patients, 90 cases in each group, two groups of patients in the gender, the basic information such as average age, average onset time on no statistical difference （P〉0.05） can be compared between groups. Two groups of patients were cerebral infarction conventional therapy, giving patients of ginkgo biloba extract injection, oral aspirin at the same time, according to the patients to antihypertension, tatins, control blood sugar and other standardized treatment. Observation group of patients using pursuant to the ADR injection; Injection, control group patients who were given a placebo in the placebo does not contain in the ADR, and conform to the requirements for the preparation of placebo, ADR mentioned with the same appearance and form. Observed two groups of patients before and after treatment for 7 days, 14 days, 21 days of NIHSS score （neurological defect scale） and the Barthel index （BI） （activities of daily living, ADL）, according to the neural function defect scale and ability evaluation of curative effect evaluation of daily living. Result Two groups of patients after treatment, the seventh day of NIHSS score and BI scores were better than the NIHSS score and BI score before treatment, the observation group and the control group after treatment in patients with 7 days of NIHSS score and BI score no statistical difference （P〉 0.05）; In 14 days after treatment, 21 days NIHSS score and BI score in observation group were significantly better than the control group patients, two groups of NIHSS score and BI score differences statistically significant （P〈0.05）, a group of patients with nerve function defect was observed patients

关 键 词：急性脑梗死 依达拉奉 临床用药 治疗效果 

分 类 号：R743.3[医药卫生—神经病学与精神病学]